Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure
Association of Cardiovascular Disease With Respiratory Disease
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past?
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors